Boston Therapeutics announces strategic acquisition of CureDM
Boston Therapeutics announces the acquisition of CureDM Group Holdings, adding a Phase 2-ready drug to their portfolio. The CureDM islet-growing peptide, HIP2B, has demonstrated clinical efficacy for type 2 diabetes by improving first phase insulin release. February 13, 2018